Microarray Analysis Reaches the Desktop

By BIO-IT World
By Robert M. Frederickson

June 17, 2004 | DNA microarrays are now ubiquitous tools in biological laboratories. Although the explosion of microarray data raises concerns about the quality of information due to inconsistent experimental design, at the same time researchers are able to include additional controls and replicates that are key to the rigorous statistical analyses necessary to render data into knowledge.

Various commercial solutions exist to analyze microarray data, from enterprise-level solutions designed primarily for large companies and institute-based support facilities to the more recently emerged desktop solutions for individual research labs. One of the pioneers of the latter format is VizX Labs, founded in 2001 in Seattle by Bob Cottingham and Tom Ranken. VizX Labs' GeneSifter package aims to provide a straightforward, easy-to-navigate Web-based solution for microarray analyses that does not require an expert's understanding of statistical software. GeneSifter frees the user from having to update databases, make refinements to the software, and maintain backups, all of which is done behind the scenes at VizX Labs.

The product was released in 2002 and has been updated quarterly, most recently in April 2004. "It was apparent that something was needed to deliver the power of microarrays to individual researchers," Cottingham says. "So we provided an accessible product that integrates statistical analysis with the determination of biological significance."

EASY AS PIE CHART: VizX Labs' GeneSifter is designed to help scientists analyze microarray data without requiring expertise in using statistical software.

Microarray powerhouses such as Affymetrix and Agilent do provide enterprise-level tools, which generally include hardware, software, and customer-support applications. These solutions tend to be directed to informatics specialists at microarray centers within larger organizations, with price tags in the six-figure range. The limited supply of computational gurus often creates data-analysis bottlenecks in these centers. Moreover, control of data analysis is taken away from bench researchers.

"The situation reminded me of the days when people were dependent on large, centralized computer centers and arcane DOS-like interfaces," Cottingham says. "Desktop alternatives like Windows freed users to wield the power of computing themselves. Web-based GeneSifter gives scientists access in a venue they are already familiar with to a solution that not only provides lists of genes, but also helps them understand the biology."

The result is the development of simpler, cheaper desktop packages designed to walk the biologist through the process with an easy-to-navigate interface, while retaining the power of traditional approaches. Increasingly seen as complementing rather than competing with enterprise solutions, suppliers such as Affymetrix have become active supporters of third-party software developers such as VizX Labs. One advantage for the individual academic researcher is that the software tends to come with a much smaller price tag: in the $3,000-$10,000 range, which is accessible to most labs.

Products similar to GeneSifter can be found in roughly the same price range. Silicon Genetics' GeneSpring is comparable, although it is not a Web-based package. Another example is Iobion's GeneTraffic and ArrayAssist. A key factor is integration of data analysis with gene ontology databases. GeneSifter provides full integration, while other packages offer a standalone data-analysis package that can be combined with database-integration software at an additional cost. Iobion's ArrayAssist package can be combined with PathwayAssist for about $10,000.



Robert M. Frederickson is a biotech writer based in Seattle. He can be reached at rfreder@yahoo.com. 




White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.